Mylan Announces Tentative Approval for Valacyclovir Hydrochloride Tablets

Announced that Mylan Pharmaceuticals Inc. has received tentative approval for its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride Tablets, 500mg (base) and 1000mg (base).

PITTSBURGH, PA, USA | Jan 31, 2007 |
  Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received tentative approval for its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride Tablets, 500mg (base) and 1000mg (base).

Valacyclovir Hydrochloride Tablets are the generic version of GlaxoSmithKline's Valtrex(R) Tablets, which had U.S. sales of approximately $1.26 billion for the same strengths in the 12-month period ending Sept. 30, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top